Chapurlat R - Search Results

1

The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: results from the FREEDOM extension.

Bone HG, Chapurlat R, Brandi ML, Brown JP, Czerwinski E, Krieg MA, Mellström D, Radominski SC, Reginster JY, Resch H, Ivorra JA, Roux C, Vittinghoff E, Daizadeh NS, Wang A, Bradley MN, Franchimont N, Geller ML, Wagman RB, Cummings SR, Papapoulos S. Bone HG, et al. Among authors: chapurlat r. J Clin Endocrinol Metab. 2013 Nov;98(11):4483-92. doi: 10.1210/jc.2013-1597. Epub 2013 Aug 26. J Clin Endocrinol Metab. 2013. PMID: 23979955 Free PMC article. Clinical Trial.

2

What PROOF proves about calcitonin and clinical trials.

Cummings SR, Chapurlat RD. Cummings SR, et al. Among authors: chapurlat rd. Am J Med. 2000 Sep;109(4):330-1. doi: 10.1016/s0002-9343(00)00539-8. Am J Med. 2000. PMID: 10996586 No abstract available.

3

Influence of smoking on the antiosteoporotic efficacy of raloxifene.

Chapurlat RD, Ewing SK, Bauer DC, Cummings SR. Chapurlat RD, et al. J Clin Endocrinol Metab. 2001 Sep;86(9):4178-82. doi: 10.1210/jcem.86.9.7848. J Clin Endocrinol Metab. 2001. PMID: 11549646 Clinical Trial.

4

Association between endogenous hormones and sex hormone-binding globulin and bone turnover in older women: study of osteoporotic fractures.

Chapurlat RD, Bauer DC, Cummings SR. Chapurlat RD, et al. Bone. 2001 Oct;29(4):381-7. doi: 10.1016/s8756-3282(01)00584-1. Bone. 2001. PMID: 11595622

5

Changes in biochemical markers of bone turnover in women treated with raloxifene: influence of regression to the mean.

Chapurlat RD, Blackwell T, Bauer DC, Cummings SR. Chapurlat RD, et al. Osteoporos Int. 2001 Dec;12(12):1006-14. doi: 10.1007/s001980170009. Osteoporos Int. 2001. PMID: 11846325 Clinical Trial.

6

Does follow-up of osteoporotic women treated with antiresorptive therapies improve effectiveness?

Chapurlat RD, Cummings SR. Chapurlat RD, et al. Osteoporos Int. 2002 Sep;13(9):738-44. doi: 10.1007/s001980200101. Osteoporos Int. 2002. PMID: 12195538

7

Incidence and risk factors for a second hip fracture in elderly women. The Study of Osteoporotic Fractures.

Chapurlat RD, Bauer DC, Nevitt M, Stone K, Cummings SR. Chapurlat RD, et al. Osteoporos Int. 2003 Apr;14(2):130-6. doi: 10.1007/s00198-002-1327-6. Epub 2003 Feb 13. Osteoporos Int. 2003. PMID: 12730779

8

Risk of fracture among women who lose bone density during treatment with alendronate. The Fracture Intervention Trial.

Chapurlat RD, Palermo L, Ramsay P, Cummings SR. Chapurlat RD, et al. Osteoporos Int. 2005 Jul;16(7):842-8. doi: 10.1007/s00198-004-1770-7. Epub 2004 Dec 3. Osteoporos Int. 2005. PMID: 15580479 Clinical Trial.

9

Drug insight: Bisphosphonates for postmenopausal osteoporosis.

Chapurlat RD, Delmas PD. Chapurlat RD, et al. Nat Clin Pract Endocrinol Metab. 2006 Apr;2(4):211-9; quiz following 238. doi: 10.1038/ncpendmet0121. Nat Clin Pract Endocrinol Metab. 2006. PMID: 16932286 Review.

10

Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study.

Sørensen HT, Christensen S, Mehnert F, Pedersen L, Chapurlat RD, Cummings SR, Baron JA. Sørensen HT, et al. Among authors: chapurlat rd. BMJ. 2008 Apr 12;336(7648):813-6. doi: 10.1136/bmj.39507.551644.BE. Epub 2008 Mar 11. BMJ. 2008. PMID: 18334527 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

404 results

Search Page

Filters